Cargando…
Uso de isoflurano como tratamiento del estado epiléptico superrefractario
INTRODUCTION. Super-refractory status epilepticus (SRSE) is a neurological condition with an important morbidity and mortality rate, for which few therapeutic options are available. Inhalation sedation with isoflurane is currently a compassionate-use treatment in Spanish intensive care units. Little...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Viguera Editores (Evidenze Group)
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478142/ https://www.ncbi.nlm.nih.gov/pubmed/37102255 http://dx.doi.org/10.33588/rn.7609.2022191 |
_version_ | 1785101283141615616 |
---|---|
author | Plans-Galván, Oriol Daniel, Xavier Rosich, Sara Blázquez-Alcaide, Vanessa Gil-Castillejos, Diana Bodí, María |
author_facet | Plans-Galván, Oriol Daniel, Xavier Rosich, Sara Blázquez-Alcaide, Vanessa Gil-Castillejos, Diana Bodí, María |
author_sort | Plans-Galván, Oriol |
collection | PubMed |
description | INTRODUCTION. Super-refractory status epilepticus (SRSE) is a neurological condition with an important morbidity and mortality rate, for which few therapeutic options are available. Inhalation sedation with isoflurane is currently a compassionate-use treatment in Spanish intensive care units. Little has been written about its usefulness in the treatment of refractory and super-refractory status epilepticus, but it appears to be a useful and safe therapeutic alternative for this condition. CASE REPORTS. This article reviews three cases of SRSE treated with isoflurane. The capacity of isoflurane to control seizures was assessed by electroencephalographic monitoring. Other variables assessed were time to seizure control, survival, functional outcome and occurrence of complications secondary to isoflurane. In the three cases reviewed, isoflurane proved to be effective for seizure control in patients affected by SRSE. Seizure control was accomplished quickly and the minimum dose required to obtain a burst-suppression pattern was titrated easily and rapidly. Despite controlling epilepsy, high mortality was observed (66.66%). This is explained by both the mortality of SRSE and the underlying pathologies of the patients who died. The use of isoflurane did not give rise to any complications. CONCLUSION. With the results obtained, it is feasible to think that the use of isoflurane is not related to lesions in the central nervous system reported in other articles, and this treatment can be considered effective and safe for the control of SRSE. |
format | Online Article Text |
id | pubmed-10478142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Viguera Editores (Evidenze Group) |
record_format | MEDLINE/PubMed |
spelling | pubmed-104781422023-09-06 Uso de isoflurano como tratamiento del estado epiléptico superrefractario Plans-Galván, Oriol Daniel, Xavier Rosich, Sara Blázquez-Alcaide, Vanessa Gil-Castillejos, Diana Bodí, María Rev Neurol Nota Clínica INTRODUCTION. Super-refractory status epilepticus (SRSE) is a neurological condition with an important morbidity and mortality rate, for which few therapeutic options are available. Inhalation sedation with isoflurane is currently a compassionate-use treatment in Spanish intensive care units. Little has been written about its usefulness in the treatment of refractory and super-refractory status epilepticus, but it appears to be a useful and safe therapeutic alternative for this condition. CASE REPORTS. This article reviews three cases of SRSE treated with isoflurane. The capacity of isoflurane to control seizures was assessed by electroencephalographic monitoring. Other variables assessed were time to seizure control, survival, functional outcome and occurrence of complications secondary to isoflurane. In the three cases reviewed, isoflurane proved to be effective for seizure control in patients affected by SRSE. Seizure control was accomplished quickly and the minimum dose required to obtain a burst-suppression pattern was titrated easily and rapidly. Despite controlling epilepsy, high mortality was observed (66.66%). This is explained by both the mortality of SRSE and the underlying pathologies of the patients who died. The use of isoflurane did not give rise to any complications. CONCLUSION. With the results obtained, it is feasible to think that the use of isoflurane is not related to lesions in the central nervous system reported in other articles, and this treatment can be considered effective and safe for the control of SRSE. Viguera Editores (Evidenze Group) 2023-05-01 /pmc/articles/PMC10478142/ /pubmed/37102255 http://dx.doi.org/10.33588/rn.7609.2022191 Text en Copyright: © Revista de Neurología https://creativecommons.org/licenses/by-nc-nd/4.0/Revista de Neurología trabaja bajo una licencia Creative Commons |
spellingShingle | Nota Clínica Plans-Galván, Oriol Daniel, Xavier Rosich, Sara Blázquez-Alcaide, Vanessa Gil-Castillejos, Diana Bodí, María Uso de isoflurano como tratamiento del estado epiléptico superrefractario |
title | Uso de isoflurano como tratamiento del estado epiléptico superrefractario |
title_full | Uso de isoflurano como tratamiento del estado epiléptico superrefractario |
title_fullStr | Uso de isoflurano como tratamiento del estado epiléptico superrefractario |
title_full_unstemmed | Uso de isoflurano como tratamiento del estado epiléptico superrefractario |
title_short | Uso de isoflurano como tratamiento del estado epiléptico superrefractario |
title_sort | uso de isoflurano como tratamiento del estado epiléptico superrefractario |
topic | Nota Clínica |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478142/ https://www.ncbi.nlm.nih.gov/pubmed/37102255 http://dx.doi.org/10.33588/rn.7609.2022191 |
work_keys_str_mv | AT plansgalvanoriol usodeisofluranocomotratamientodelestadoepilepticosuperrefractario AT danielxavier usodeisofluranocomotratamientodelestadoepilepticosuperrefractario AT rosichsara usodeisofluranocomotratamientodelestadoepilepticosuperrefractario AT blazquezalcaidevanessa usodeisofluranocomotratamientodelestadoepilepticosuperrefractario AT gilcastillejosdiana usodeisofluranocomotratamientodelestadoepilepticosuperrefractario AT bodimaria usodeisofluranocomotratamientodelestadoepilepticosuperrefractario |